Mechanistic differentiation of PI3K/mTOR, Aurora kinase and EZH2 inhibitor classes by comparative cancer cell line profiling by Uitdehaag, J.C.M, De Roos, J.A.D.M, Prinsen, M.B.W, De Vetter, J.R.F, Dylus, J, Van Doornmalen, A.M, Van Gerwen, S.J.C, De Man, J, Buijsman, R.C, Zaman, G.J.R

Get full text

Cell panel profiling of pre-clinical and clinical anti-cancer agents reveals conserved therapeutic clusters and differentiates the mechanism of action of different PI3K/mTOR, Auror... by Uitdehaag, J.C.M, De Roos, J.A.D.M, Prinsen, M.B.W, Willemsen-Seegers, N, De Vetter, J.R.F, Dylus, J, Van Doornmalen, A.M, Kooijman, J, Sawa, M, Van Gerwen, S.J.C, De Man, J, Buijsman, R.C, Zaman, G.J.R

Get full text

349 Synergistic drug combinations that target beta-catenin-driven and MYC-driven cancers by Uitdehaag, J.C.M, Spijkers-Hagelstein, J.A.P, de Roos, J.A.D.M, van Doornmalen, A.M, Prinsen, M.B.W, de Man, J, Buijsman, R.C, Zaman, G.J.R

Get full text

655: Identification of new synergistic drug combinations on basis of cell panel profiling by Uitdehaag, J.C.M, De Roos, J.A.D.M, Spijkers-Hagelstein, J.A.P, Van Doornmalen, A.M, Prinsen, M.B.W, De Man, J, Buijsman, R.C, Zaman, G.J.R

Get full text

183 (PB171): A novel kinase degrader-based payload for the development of potent Degrader Antibody Conjugates (DACs) by Uitdehaag, J.C., van Mil, Y.G.T.H., de Man, J., Muller, M., van Cauter, F., van Gemert, S.P.W., Hoffmann, M.J., Mulder, W.R., Prinsen, M.B.W., Sterrenburg, J.G., Vu, D., de Wit, J.J.P., Ensing, E., Buijsman, R.C.

Get full text

151 (PB139): CFON-026, a best-in-class macrocyclic non-covalent inhibitor of BTK (WT) and all clinically relevant BTK resistance mutations by Van Mil, Y., Uitdehaag, J.C., de Man, J., Muller, M., van Cauter, F., van Gemert, S.P.W., Hoffmann, M.J., Mulder, W.R., Prinsen, M.B.W., Sterrenburg, J.G., Vu, D., de Wit, J.J.P., Ensing, E., Buijsman, R.C.

Get full text

580 - Mechanistic differentiation of PI3K/mTOR, Aurora kinase and EZH2 inhibitor classes by comparative cancer cell line profiling by Uitdehaag, J.C.M., De Roos, J.A.D.M., Prinsen, M.B.W., De Vetter, J.R.F., Dylus, J., Van Doornmalen, A.M., Van Gerwen, S.J.C., De Man, J., Buijsman, R.C., Zaman, G.J.R.

Get full text

52 - Cell panel profiling of pre-clinical and clinical anti-cancer agents reveals conserved therapeutic clusters and differentiates the mechanism of action of different PI3K/mTOR,... by Uitdehaag, J.C.M., De Roos, J.A.D.M., Prinsen, M.B.W., Willemsen-Seegers, N., De Vetter, J.R.F., Dylus, J., Van Doornmalen, A.M., Kooijman, J., Sawa, M., Van Gerwen, S.J.C., De Man, J., Buijsman, R.C., Zaman, G.J.R.

Get full text

PO-484 Development of a two-step screening-and-confirmation approach to efficiently identify synergistic drug combinations with the PARP inhibitor niraparib by Prinsen, MBW, Vetter, JRF De, Dylus, J, Roos, JADMDe, Gerwen, SJC Van, Buijsman, RC, UItdehaag, JCM

Get full text

PO-456 Cell line panel profiling of all clinically approved kinase inhibitors for cancer treatment by Kooijman, JJ, Uitdehaag, JCM, Roos, JADMDe, Vetter, JRF De, Prinsen, MBW, Dylus, J, Man, J De, Gerwen, SJC Van, Buijsman, RC, Zaman, GJR

Get full text